Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

What a $19 Million CyberArk Buy Signals for Long-Term Investors Amid a 43% Stock Surge ↗

December 23, 2025

The stock has already soared, the numbers keep accelerating, and one concentrated fund just made it a core holding anyway.

Via The Motley Fool

Topics Regulatory Compliance

What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag ↗

December 23, 2025

The stock is roughly flat this past year, but the fundamentals quietly moved in the right direction, and that disconnect likely caught this fund’s attention.

Via The Motley Fool

Topics Regulatory Compliance

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal ↗

September 30, 2025

Via Stocktwits

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Halper Sadeh LLC Encourages CADE, THS, CMA, MRUS Shareholders to Contact the Firm to Discuss Their Rights

December 03, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

From Halper Sadeh LLC

Via GlobeNewswire

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

October 24, 2025

From Merus N.V.

Via GlobeNewswire

HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

October 23, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

From Halper Sadeh LLC

Via GlobeNewswire

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

October 23, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From Merus N.V.

Via GlobeNewswire

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

From Merus N.V.

Via GlobeNewswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders

October 09, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders

October 07, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders

October 04, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Unusual volume stocks are being observed in Thursday's session. ↗

October 02, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders

October 01, 2025

From Halper Sadeh LLC

Via GlobeNewswire

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

September 30, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

September 30, 2025

Via Benzinga

Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down ↗

September 30, 2025

U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by...

Via Chartmill

Topics Cannabis

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

Let's take a look at the stocks that are in motion in today's session. ↗

September 29, 2025

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders

September 29, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings ↗

September 29, 2025

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.